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WHAT'S KNOWN ON THIS SUBJECT
The iodide recommendation for preterm enteral nutrition is 30-40μg/kg/day but 1μg/kg/day for parental nutrition. Iodide is needed to produce thyroid hormones, which are essential for normal brain development. Observational studies report associations between low postnatal thyroid hormones and compromised neurodevelopment.
WHAT THIS STUDY ADDS
The neutral results do not indicate that the iodide content of parenteral nutrition should routinely be increased from the current level to match the enteral level. This evidence may not apply to preterm infants on primarily parental nutrition over prolonged periods.
INTRODUCTION
Thyroid hormone is essential for normal brain development in-utero and for the first two years of life. Brain damage through deficiency of thyroxine (T4) is irreversible. Congenital hypothyroidism is the most extreme form of thyroid hormone deficiency. A milder form of deficiency, transient hypothyroxinemia, is characterized by low or normal levels of thyrotropin (TSH) and low T4 levels. Transient hypothyroxinemia is common in preterm infants, 1 its etiology is multifactorial [2] [3] [4] [5] [6] and includes iodide deficiency. 7, 8 The European guideline for preterm neonatal enteral iodide intake is 11-55μg/kg/day; 9 although, evidence from balance studies suggests that the intake for healthy preterm infants should be a minimum of 30-40μg/kg/day. 7 The guideline for parenteral nutrition is 1μg/kg/day. 10, 11 The iodide requirement of extreme preterm infants is complex and difficult to assess. Neonates have very small iodine reserves, 12 are vulnerable to iodine toxicity, 13 and their immature physiology can demand higher levels of some nutrients, especially ions, relative to the term neonate. 14 Extreme preterm infants are fed parenterally until their clinical condition improves, when the contribution of parenteral to formula/breast milk gradually decreases. Iodide balance studies of preterm infants show that they are in negative iodide balance 7, 8 until their intake of nutrition is primarily enteral. Iodine is an essential component of thyroid hormones and because the preterm infant has small iodide reserves within the thyroid gland, 12 it is essential that daily nutrients provide sufficient iodide to support T4 production.
Although transient hypothyroxinemia was formerly thought of as clinically harmless, recent studies show associations with neurodevelopmental compromise. [15] [16] [17] [18] [19] [20] Infants with transient hypothyroxinemia perform less well on developmental tests and this compromise persists into at least late childhood. 18 These children are predicted to perform less well at school, which has consequences for their lifetime achievements and well-being. The link between suboptimal neurodevelopment and the early iodide status of preterm infants is not well known. It is also Page | 6 unknown whether iodide supplementation can confer a benefit to later outcome. Our aim was to determine whether iodine supplementation leads to improved neurodevelopmental outcome in extreme preterm infants at 2 years of age.
PATIENTS AND METHODS
I2S2 was a UK, randomized, placebo-controlled trial. 21 The trial was approved by Tayside Infants were eligible if they were <42 hours old, born <31 weeks' gestation in one of the trial recruiting hospitals, and had a realistic prospect of survival. The only exclusion criterion was maternal exposure to iodide during pregnancy or delivery (e.g. the use of topical iodides for skin antisepsis prior to epidural/caesarean section/other surgery, or from exposure to iodinated contrast media. Women absorbing iodide from multi-vitamins or from their habitual diet were eligible for enrollment.)
RANDOMIZATION AND MASKING
Eligible infants were randomized to intervention or placebo (with roughly equal probability) using a secure website with 24/7 telephone back-up. 21 The randomization program used a bespoke minimisation algorithm to ensure balance across hospitals on gender and gestational age (by individual week from 22-25 weeks, 26-27 weeks, and 28-30 weeks (Supplementary 
PROCEDURES
Mother/infants were recruited by I2S2 trained staff. Trial solutions were prescribed by medical staff following I2S2 guidance sheets. Infants received either the intervention (sodium iodide diluted to an iodide content of 75μg/ml) or placebo (sodium chloride diluted to a chloride content of 75μg/ml). The packaging and visual appearance of trial solutions were identical and the solutions could be given either parenterally or enterally. (Enteral absorption of iodide is almost complete, thus the parenteral and enteral intakes should be the same.) The dose was 30μg/kg/day, given daily from randomization until the equivalent of 34 weeks' gestational age (had the fetus remained in-utero referred to hereafter as equivalent gestational age). personnel specifically trained to use the Bayley-III and random performances were videorecorded and audited. The setting for the interventional phase was the neonatal unit and followup at two years was undertaken in a hospital close to the infants' home.
There were no restrictions on medications or treatments permitted during the trial, including
Levo-thyroxine if prescribed. Infants were immediately withdrawn from receiving trial solutions if they were exposed to topical iodide containing antiseptics or if iodinated contrast media was given. Such infants were monitored locally for the biochemical features of iodine toxicity on thyroid dysfunction. These infants were included in all other aspects of the trial, including the two-year follow-up.
TRIAL OUTCOMES
The primary outcome was neurodevelopmental status defined by the three domains of the 
STATISTICAL ANALYSIS
To detect a difference in mean Bayley-III score of 6 units (assuming a SD of 15) and taking into account anticipated mortality, with 90% power and a two-sided 5% level of significance, a target sample size of 1400 infants was required (Section 2, Appendix). 21 Primary outcome analyses were by intention-to-treat. Outcomes were compared for all infants allocated to intervention or placebo, regardless of whether, or for how long, they received trial solutions.
Baseline characteristics were described by randomization allocation, using numbers with percentages for binary and categorical variables, and means and SD for continuous data. For
the three main domains of the Bayley-III, the difference in mean score between the iodide and placebo groups was assessed with the independent samples T test, using a 5% 
RESULTS
Between March 2010 and December 2012, 1275 infants were enrolled from 21 hospitals. Two infants were randomized in error and 14 parents withdrew consent for their infant's data to be used ( Figure 1 ). Bayley-III assessments were available for 498/631 (79%) iodide and 499/628 (79%) placebo supplemented infants ( Figure 1 ). Limited follow-up data were available for an additional 59/631 (9%) iodide and 48/628 (8%) placebo supplemented infants. At baseline, infant/maternal characteristics were very similar ( Table 1) .
Sixty-five (65/631, 10%) infants from the iodide group and 66 (66/628, 11%) infants from the placebo group died between randomization and the two year follow-up. The main causes of death in the intervention phase were necrotizing enterocolitis (31% in each group), followed by infection (iodide group 23%, placebo 20%) (Supplementary Table 2 , Appendix). During the neonatal period, 11 infants were treated with Levo-thyroxine for variable durations and variable dosages (9 in the iodide arm, 2 in the placebo) and received a working clinical diagnosis of hypothyroidism. At two years of age, 13 infants (7 from the original 11, and 6 additional infants) were receiving Levothyroxine (8 iodide and 5 placebo); no infant was reported to have thyroid toxicity.
OUTCOMES
There was no significant difference between groups in the main domains of the Bayley-III: mean difference in Cognitive score, -0.34, 95% CI -2.57 to 1.89; in Motor composite score, 0.21, 95%
CI -2.23 to 2.65; and in Language composite score, -0.05, 95% CI -2.48 to 2.39 (Table 2 ). There were no differences when the analyses were repeated for survivors, either unadjusted or adjusted
Page | 11 (Supplementary Table 3a -e, Appendix). Overall, the frequency of postnatal conditions was similar between the groups. The numbers of infants at each level of nursing care, the amount of parenteral nutrition (as a percentage of the total nutrition) at each postnatal measurement day, and the prescribed drug usage was the same in the iodide and placebo supplemented groups (Table 2, Supplementary Table 4 , Appendix).
There were no significant differences between levels of T4 or TBG ( Figure 2 , Supplementary   Figure 1 , Appendix). Levels of TSH were generally slightly higher in the iodide arm, with significant differences evident at postnatal days 7 and 14 ( Figure 2 ).
PRE-SPECIFIED SUB-GROUP ANALYSIS
The differences in mean Bayley-III scores between the iodide and placebo groups did not differ appreciably by gestational age-group or maternal thyroid disease status (Supplementary Figure   2) ; nor by neonatal illness, which was approximated by using the level of nursing care 
ADVERSE EVENTS
There were no SUSARs reported during the trial. Sixty adverse events were reported for the iodide group and 28 for the placebo group. Because some UK newborn screening laboratories instigate follow-up tests at TSH levels ≥6mU/l, we classified this level as an adverse event to ensure that these infants were investigated quickly by the local unit. The highest TSH level
recorded was an isolated value of 34 mU/L; such mildly raised TSHs were not considered clinically as an adverse event (Supplementary Table 6 , Appendix).
DISCUSSION
The evidence from this large pragmatic trial shows no overall benefit of iodide supplementation on neurodevelopment, measured at two years, for preterm infants. The iodide supplemented group had slightly higher levels of TSH (but not T4 or TBG) than the placebo group. The trial shows no adverse consequences associated with iodide supplementation at 30μg/kg/day.
The results of the trial were unexpected and do not agree with the evidence from observational studies. The impetus for this trial was the accumulating evidence from observational studies that hypothyroxinemia is associated with compromised neurodevelopment. [15] [16] [17] [18] [19] [20] In response to this evidence, some researchers explored the use of treatment with thyroxine 23, 24 but there were insufficient data to determine whether treatment was beneficial. Only one study of thyroxine supplementation in preterm infants included long-term neurodevelopmental outcome and the results were equivocal. 23 In that study, infants receiving thyroxine supplementation (compared to placebo) scored 18 points higher aged two years on the Bayley-II Cognitive component, but only if they were <27 weeks gestation; supplemented infants born ≥27 weeks scored 10 points lower than nonsupplemented infants. Subsequent follow-up at 5.7 25 and 10 years 26 confirmed these findings.
Despite the equivocal results, a recent survey indicated that clinical treatment with thyroxine has increased 2.6 fold in neonates born <27 weeks' gestation. 27 Continuing clinical interest in hypothyroxinemia led to a phase 1 placebo-controlled trial of thyroxine with triiodothyronine therapy. 24 That trial showed changes in T4 with continuous supplement of low-dose thyroxine over 42 days, but no benefit of supplementation at three years of age in Bayley-III Cognitive score, albeit the study included very few infants. 28 In our trial the iodide arm
showed no difference in Bayley-III scores between infants classified as hypothyroxinemic and euthyroid, whereas in the placebo arm, the hypothyroxinemic group performed worse on the Bayley-III than the euthyroid group, especially in the language domain. This result suggests that hypothyroxinemia may not simply be an epiphenomenon of non-thyroidal illness. The results also suggest that iodide supplementation alone, at 30μg/kg/day, without the addition of T4 replacement therapy, can mitigate the adverse consequences of hypothyroxinemia. This is important because T4 replacement therapy may be harmful if it is given to infants who do not require it. 23 Explanation of the neutral impact of iodide supplementation that we observe is hindered by the lack of iodide balance data, especially urinary iodide excretion. We considered monitoring urinary iodide during the active phase of the trial but concluded that the collection, storage, transport and analysis of these data would have been prohibitively costly.
Instead, we relied upon the evidence base, which suggests that: preterm infants are vulnerable to iodide deficiency while on parenteral nutrition, 7, 8 breast and formula milk provide highly variable amounts of iodide, 29 drugs and supplements typically given to neonates contain miniscule amounts of iodide, 8 and the UK population is mildly iodide deficient, 30,31 which exaggerates thyroid dysfunction.
The neutral effect of this trial has at least three possible explanations: first, the placebo infants received iodide from hitherto unknown iodine sources; second, the level of iodide supplementation was too low; and thirdly the Bayley-III is insufficiently sensitive. We do not believe that the infants in the placebo group were exposed to additional iodide. There are only two main sources of extraneous iodide that neonates are routinely exposed: topical iodide containing skin cleansers and variable quantities of free iodide from exposure to iodinated contrast media. 32 Any infant exposed to these sources during the I2S2 trial was immediately withdrawn from trial solutions. A study in 2012 33 reported that parenteral nutrition contained
almost no iodine and, with no evidence to the contrary, 1-3µg/kg/day 8 remains the best estimate of likely intake of the placebo group. The recommended level of iodide intake of 30-40µg/kg/day for preterm infants is based on balance data for healthy preterm infants at around one month of age. 7 It is conceivable that the trial supplement of 30µg/kg/day is too low an amount for sick, preterm neonates receiving parenteral nutrition, whose immature physiology may require higher amounts of nutrients relative to the term infant. The extra nutrient requirement of the extreme preterm infant has already been shown for other ions, where the fractional urinary excretion is high in the most extreme preterm infants, but with maturation of the kidney this declines. 14 It is also possible that 30µg/kg/day is too low for a mild-to-moderately iodine deficient population such as the UK. Although it is not normally appropriate to investigate sub-group variables that could be affected by the trial intervention, we felt it was important to do so on this occasion and specified a priori and in our statistical analysis plan our intention. The only known human role for iodine is for the production of thyroid hormones and we hypothesized that the iodide intervention (but not the placebo) would positively affect the Bayley score via the intermediary of (increased) thyroid hormone with a concomitant decrease in the incidence of hypothyroxinemia. There is no evidence or plausible reason why iodide would have a direct or independent effect on the Bayley Score, and other factors which would contribute an
Page | 15 independent effect on the Bayley score would be equally distributed between the arms of the trial due to random allocation. Thus the typical confounders of interpretation are mitigated.
This trial has three findings. Iodide supplementation to all infants born <31 weeks' gestation confers no benefit to neurodevelopment measured by the Bayley-III scales at 2 years of age.
Giving iodide at 30μg/kg/day was associated with no adverse consequences. Finally, there is only weak evidence that the sub-group of hypothyroxinemic infants gained benefit from iodide supplementation in one of three main Bayley-III domains. 
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STUDY OVERSIGHT

B
RDS denotes Respiratory Distress Syndrome
C
The majority of other is codeine/paracetamol (iodide 19/25, placebo 22/32) Percentages only add to 100% when there are no missing data.
There were no significant differences between the groups for any variables. SD denotes standard deviation Page | 22 591 (94) 262 (42) 192 (31) 128 (20) 522 (83) 283 (45) 9 (1) 13 (2) 27 (4) 37 (6) 7 (1) 385 (61) 153 (24) N=628 581 (93) 235 (37) 195 (31) 103 (16) 519 (83) 258 (41) 7 (1) 12 (2) 38 (6) 26 (4) 6 (1) 392 (62) 147 (23) Odds ratio (99% CI) Missing outcomes for losses to follow-up and for infants who were withdrawn but allowed their data to be used were imputed B In the four Bayley-III subtest scores deaths were scored as 1 or 0, reflecting their minimum scores.
C Two infants had no postnatal data collection forms D The odds ratio was any cerebral pathology compared to no cerebral pathology E N varies due to deaths or to infant withdrawals F N varies due to deaths, infant withdrawals and missing data F Late sequelae of ventilation: death due to progressive respiratory failure after one week of age without an acute precipitating cause. This should include babies dying with classic bronchopulmonary dysplasia after 28 days.
G The numbers of deaths in this table are those recorded during the intervention phase of the trial; the numbers are lower than those shown in Figure 1 of the paper as that figure includes deaths which occurred between the end of the intervention phase and the two year follow up.
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